![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
The collaboration aims to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer by leveraging etherna’s innovative mRNA/LNP technology platform and LNP formulations with Almirall’s leading expertise in dermatology.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Almirall
Deal Size: $327.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 12, 2023